Enabling RNA/DNA therapeutics development from Discovery to Human clinical trials. Our portfolio includes a wide range of products, from the gold standard cationic polymer-based in vivo–jetPEI®, which is ready-to-use and ensures the delivery of any type of nuclec acids, to ready-to-use lipid-based nanoparticles: in vivo-jetRNA®+, dedicated to the delivery of mRNA both in vivo and ex vivo, and cationic lipids used as bricks to formulate and improve lipid nanoparticles (LNPs) formulation to open up new possibilities for mRNA-based therapies.

LipidBrick® library : Lipid-based nanoparticles (LNPs) represent one of the most promising RNA delivery systems, not only due to their efficacy, but also to the ease of production achieved through precise controlled mixing technique known as microfluidics and the scalability of production. Still, they present some limitations related to toxicity, targeting, limited biodistribution through systemic administration which mainly results in liver uptake. For this purpose, Polyplus® has recently developed a library of cationic lipids (LipidBrick®), which represents a remarkable innovation compared with conventional cationic lipids by ensuring reduced toxicity of LNPs and extending their use beyond the liver.  

in vivo-jetRNA®+ : As an alternative to LNPs, we have also developed a ready-to-use lipid based transfection reagent in vivo-jetRNA®+ consisting of lipid-based nanoparticles specifically engineered to deliver mRNA and saRNA. This reagent is very efficient and leads to gene expression comparable to LNPs in vivo and ex vivo. It can therefore be used as a ready-to-use formulation for immunizations purposes, proof-of-concept studies, or to benchmark LNP formulations under development for in vivo or ex vivo applications. 

Webinar replay : Fine-tuning your mRNA-LNP formulation with an innovative cationic lipid library

Watch Webinar